In Sept. 2023, Insilico announced an exclusive global license agreement with Exelixis – granting Exelixis the right to develop and commercialize ISM3091, a potentially best-in-class small molecule inhibitor of USP1, which has emerged as a synthetic lethal target in BRCA-mutated tumors. The agreement included an $80 million upfront fee in exchange for Insilico granting Exelixis an exclusive, worldwide license to develop and commercialize ISM3091 and other USP1 targeted compounds. Insilico will also be eligible to receive future development, commercial, and sales-based milestone payments, as well as tiered royalties on net sales.